Coherus Oncology
CHRS
167 hedge funds and large institutions have $1.41B invested in Coherus Oncology in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 56 increasing their positions, 43 reducing their positions, and 20 closing their positions.
217% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $4.99M
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
30% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 43
14% more funds holding
Funds holding: 146 → 167 (+21)
3.11% more ownership
Funds ownership: 96.32% → 99.43% (+3.1%)
5% less capital invested
Capital invested by funds: $1.47B → $1.41B (-$67.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$26.7M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$14.1M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$13.3M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$9.96M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$9.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$15.3M |
| 2 |
JP Morgan Chase
New York
|
-$11.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.99M |
| 4 |
HP
Hound Partners
New York
|
-$9.47M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.38M |
CHRS Hedge Fund Activity: Q3 2019 in Review
167 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2019, worth a combined $1.41B — down 4.6% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CHRS positions and 20 closed out — a net gain of 23 holders — while 56 added to existing stakes and 43 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $26.7M. The largest seller was PFM Health Sciences, cutting an estimated $15.3M.
- 167 institutional investors held Coherus Oncology (CHRS) as of Q3 2019, up from 146 in Q2 2019.
- Funds reported $1.41B of Coherus Oncology stock for Q3 2019, down 4.6% quarter-over-quarter.
- 43 funds opened new Coherus Oncology positions in Q3 2019 and 20 closed out, a net change of +23 holders.
- The largest Coherus Oncology buyer in Q3 2019 was Rubric Capital Management (New York), an estimated $26.7M added.
- The largest Coherus Oncology seller in Q3 2019 was PFM Health Sciences, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2019.